Das S - Search Results

1

Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy.

Wong SK, Beckermann KE, Johnson DB, Das S. Wong SK, et al. Among authors: das s. Expert Opin Biol Ther. 2021 Dec;21(12):1623-1634. doi: 10.1080/14712598.2021.1921140. Epub 2021 May 4. Expert Opin Biol Ther. 2021. PMID: 33890832

2

Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.

Roberts JA, Gonzalez RS, Das S, Berlin J, Shi C. Roberts JA, et al. Among authors: das s. Hum Pathol. 2017 Dec;70:49-54. doi: 10.1016/j.humpath.2017.10.003. Epub 2017 Oct 14. Hum Pathol. 2017. PMID: 29037958 Free PMC article.

3

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Wang DY, et al. Among authors: das s. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. JAMA Oncol. 2018. PMID: 30242316 Free PMC article.

4

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Das S, Johnson DB. Das S, et al. J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8. J Immunother Cancer. 2019. PMID: 31730012 Free PMC article. Review.

5

Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy.

Roth MT, Das S. Roth MT, et al. Among authors: das s. Expert Rev Anticancer Ther. 2021 Feb;21(2):229-238. doi: 10.1080/14737140.2021.1851201. Epub 2020 Dec 4. Expert Rev Anticancer Ther. 2021. PMID: 33183114 Free PMC article.

6

Promising New Agents for Colorectal Cancer.

Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Das S, et al. Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z. Curr Treat Options Oncol. 2018. PMID: 29752549 Free PMC article. Review.

7

Harnessing the Immune System in Pancreatic Cancer.

Das S, Berlin J, Cardin D. Das S, et al. Curr Treat Options Oncol. 2018 Aug 20;19(10):48. doi: 10.1007/s11864-018-0566-5. Curr Treat Options Oncol. 2018. PMID: 30128712 Free PMC article. Review.

8

¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.

Das S, Al-Toubah T, El-Haddad G, Strosberg J. Das S, et al. Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023-1031. doi: 10.1080/17474124.2019.1685381. Epub 2019 Oct 30. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31652074 Free PMC article. Review.

9

Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Das S, et al. Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14. Oncologist. 2020. PMID: 31943525 Free PMC article.

10

All in the Levels-Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer.

Das S, Cimino S, Davis S, Ciombor K. Das S, et al. Oncologist. 2021 Jan;26(1):e186-e188. doi: 10.1002/onco.13526. Epub 2020 Sep 28. Oncologist. 2021. PMID: 32945067 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,765 results

Search Page

Filters